基于伏邪理论探讨干扰素治疗慢性乙型肝炎的疗效特点及中医药协同减毒增效机制

王石中; 郑润锈; 孙克伟

doi:10.12449/JCH251024

基于伏邪理论探讨干扰素治疗慢性乙型肝炎的疗效特点及中医药协同减毒增效机制

DOI: 10.12449/JCH251024

1.
湖南中医药大学研究生院，长沙 410208
2.
湖南中医药大学第一附属医院肝病科，长沙 410007

基金项目:

国家自然科学基金 (8197152432);

2023年湖南中医药大学双一流学科建设项目 (6001001007)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：王石中负责文章设计，资料分析，撰写论文；郑润锈参与收集数据，修改论文；孙克伟负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
孙克伟， keweisun550@163.com （ORCID： 0009-0003-6411-6707）

计量
- 文章访问数: 50
- HTML全文浏览量: 16
- PDF下载量: 11
- 被引次数: 0
出版历程
- 收稿日期: 2025-03-12
- 录用日期: 2025-04-14
- 出版日期: 2025-10-25

Efficacy of interferon in treatment of chronic hepatitis B and the synergistic mechanism of traditional Chinese medicine in toxicity reduction and efficacy enhancement： A study based on the theory of latent pathogens

1.
Graduate School of Hunan University of Chinese Medicine，Changsha 410208，China
2.
Department of Hepatology，The First Hospital of Hunan University of Chinese Medicine，Changsha 410007，China

Research funding:

National Natural Science Foundation of China (8197152432);

Double First-Class Discipline Construction Project of Hunan University of Chinese Medicine in 2023 (6001001007)

More Information

Corresponding author: SUN Kewei， keweisun550@163.com （ORCID： 0009-0003-6411-6707）

摘要

摘要: 在传统中医理论体系中，伏邪深藏于厥阴肝胆是慢性乙型肝炎的核心病机。干扰素能调节免疫、清除病毒，通过透邪祛毒可实现临床治愈，但其治疗初期常出现瞑眩反应，长期使用易损伤气血，且疗效依赖于患者自身正气。中医药协同干扰素治疗时，根据患者动态变化的病机调整配伍，不仅能减少不良反应，增强疗效，还可扩大干扰素的适用人群，改善患者的临床症状。
- 乙型肝炎，慢性 /
- 伏邪 /
- 干扰素类 /
- 中医药疗法
Abstract: In the traditional theoretical system of traditional Chinese medicine， latent pathogenic factors deeply hiding in the liver and gallbladder of the Jueyin meridian are the core pathogenesis of chronic hepatitis B. Interferon can regulate immunity and eliminate viruses， and clinical cure can be achieved by penetrating and removing pathogenic factors and toxins. However， it often causes dizziness and confusion reactions in the initial stage of treatment， and long-term use can damage Qi-blood； furthermore， its therapeutic effect depends on the patient’s own vital Qi. When traditional Chinese medicine is used in combination with interferon， drug compatibility should be adjusted according to the dynamic changes of pathogenesis， which can reduce adverse reactions， enhance the therapeutic outcome， expand the applicable population of interferon， and improve the clinical symptoms of patients.
- Hepatitis B， Chronic /
- Latent Pathogens /
- Interferons /
- Traditional Chinese Medicine Therapy

HTML全文

参考文献(30)

[1]	PAN F. Clinical cure is the ideal goal of chronic hepatitis B treatment[J]. China Med Pharm, 2024, 14( 12): 1- 3. DOI: 10.3969/j.issn.2095-0616.2024.12.001. 潘锋. 临床治愈是慢乙肝治疗的理想目标[J]. 中国医药科学, 2024, 14( 12): 1- 3. DOI: 10.3969/j.issn.2095-0616.2024.12.001.
[2]	NING Q, WU D, WANG GQ, et al. Roadmap to functional cure of chronic hepatitis B: An expert consensus[J]. J Viral Hepat, 2019, 26( 10): 1146- 1155. DOI: 10.1111/jvh.13126.
[3]	ZHANG WH, ZHANG DZ, DOU XG, et al. Consensus on pegylated interferon alpha in treatment of chronic hepatitis B[J]. J Clin Transl Hepatol, 2018, 6( 1): 1- 10. DOI: 10.14218/JCTH.2017.00073.
[4]	LAI YZ, WANG JB, YIN JH, et al. Treatment and syndrome differentiation of chronic hepatitis B based on theory of“warm disease caused by incubating pathogens”[J]. Acta Chin Med Pharmacol, 2018, 46( 3): 71- 74. DOI: 10.19664/j.cnki.1002-2392.180086. 赖英哲, 王静滨, 尹建华, 等. 浅谈从“伏邪温病”理论辨治慢性乙型肝炎[J]. 中医药学报, 2018, 46( 3): 71- 74. DOI: 10.19664/j.cnki.1002-2392.180086.
[5]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
[6]	ZAGHOUANI H, HOEMAN CM, ADKINS B. Neonatal immunity: Faulty T-helpers and the shortcomings of dendritic cells[J]. Trends Immunol, 2009, 30( 12): 585- 591. DOI: 10.1016/j.it.2009.09.002.
[7]	RUDD BD, VENTURI V, SMITH NL, et al. Acute neonatal infections‘lock-in’ a suboptimal CD8⁺ T cell repertoire with impaired recall responses[J]. PLoS Pathog, 2013, 9( 9): e1003572. DOI: 10.1371/journal.ppat.1003572.
[8]	ROUSHAN MR, BIJANI A, RAMZANINEJAD S, et al. HBeAg seroconversion in children infected during early childhood with hepatitis B virus[J]. J Clin Virol, 2012, 55( 1): 30- 33. DOI: 10.1016/j.jcv.2012.05.007.
[9]	WANG ZW, MENG CP. Observation on curative effect of Xinhuang tablet in preventing and treating influenza-like symptoms caused by interferon[J]. Strait Pharm J, 2008, 20( 5): 88. DOI: 10.3969/j.issn.1006-3765.2008.05.049. 王志炜, 孟春萍. 新癀片防治干扰素所致流感样症状疗效观察[J]. 海峡药学, 2008, 20( 5): 88. DOI: 10.3969/j.issn.1006-3765.2008.05.049.
[10]	WANG JH, WANG LG, HUANG LX. Characteristics, mechanisms and significance of Mingxuan reactions[J]. China J Tradit Chin Med, 2022, 37( 4): 1982- 1985. 王建辉, 王伶改, 黄利兴. 论瞑眩反应特点及其机制与意义[J]. 中华中医药杂志, 2022, 37( 4): 1982- 1985.
[11]	ZHOU B. Side effect of α-interferon on treatment of chronic hepatitis and its clinical intervention[D]. Guangzhou: Southern Medical University, 2012. 周斌. α-干扰素治疗慢性病毒性肝炎的副作用及其临床干预[D]. 广州: 南方医科大学, 2012.
[12]	HOU FQ, YIN YL, ZENG LY, et al. Clinical effect and safety of pegylated interferon-α-2b injection(Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients[J]. Chin J Hepatol, 2017, 25( 8): 589- 596. DOI: 10.3760/cma.j.issn.1007-3418.2017.08.007. 侯凤琴, 尹玉玲, 曾兰怡, 等. 聚乙二醇干扰素α-2b注射液(Y型, 40 kD)治疗HBeAg阳性慢性乙型肝炎患者的临床效果和安全性[J]. 中华肝脏病杂志, 2017, 25( 8): 589- 596. DOI: 10.3760/cma.j.issn.1007-3418.2017.08.007.
[13]	YU JH. Correlation between TCM constitution distribution and efficacy of pegylated interferon α in HBeAg-positive chronic hepatitis B patients[D]. Hefei: Anhui University of Chinese Medicine, 2017. 余金花. HBeAg阳性慢性乙型肝炎患者中医体质分布与聚乙二醇干扰素α疗效的相关性研究[D]. 合肥: 安徽中医药大学, 2017.
[14]	WU D, WANG P, HAN MF, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: The Endeavor study[J]. Hepatol Int, 2019, 13( 5): 573- 586. DOI: 10.1007/s12072-019-09956-1.
[15]	NING Q, HAN MF, SUN YT, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial(OSST trial)[J]. J Hepatol, 2014, 61( 4): 777- 784. DOI: 10.1016/j.jhep.2014.05.044.
[16]	WANG JL, XI DY, YAN XB, et al. Predictive factors and nomogram construction for HBsAg clearance in HBeAg-negative chronic hepatitis B patients treated with pegylated interferon α-2b[J]. J Clin Hepatol, 2023, 39( 12): 2809- 2816. DOI: 10.3969/j.issn.1001-5256.2023.12.010. 王佳露, 席德扬, 颜学兵, 等. 聚乙二醇干扰素α-2b治疗HBeAg阴性慢性乙型肝炎患者实现HBsAg清除的预测因素及列线图构建[J]. 临床肝胆病杂志, 2023, 39( 12): 2809- 2816. DOI: 10.3969/j.issn.1001-5256.2023.12.010.
[17]	LI SY, LI H, XIONG YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study[J]. J Viral Hepat, 2017, 24( Suppl 1): 12- 20. DOI: 10.1111/jvh.12755.
[18]	REN PP, CAO ZJ, MO RD, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk[J]. Expert Opin Biol Ther, 2018, 18( 10): 1085- 1094. DOI: 10.1080/14712598.2018.1518423.
[19]	HE XJ, LONG YZ, ZHOU J, et al. Monitoring the therapeutic effect of pegylated interferon on chronic hepatitis B patients with low viral load by serum HBV RNA[J]. Clin J Med Offic, 2023, 51( 10): 1091- 1095. DOI: 10.16680/j.1671-3826.2023.10.27. 贺潇瑾, 龙云铸, 周娟, 等. 血清乙型肝炎病毒RNA监测聚乙二醇干扰素治疗核苷(酸)类似物经治低病毒载量慢性乙型肝炎患者疗效[J]. 临床军医杂志, 2023, 51( 10): 1091- 1095. DOI: 10.16680/j.1671-3826.2023.10.27.
[20]	LI K, NING HB, JIN HM, et al. Analysis of the effect of pegylated interferon α-2b on serum HBsAg clearance rate in patients with chronic hepatitis B[J]. J Clin Hepatol, 2023, 39( 8): 1819- 1824. DOI: 10.3969/j.issn.1001-5256.2023.08.009. 李宽, 宁会彬, 靳慧鸣, 等. 聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者血清HBsAg清除率的效果分析[J]. 临床肝胆病杂志, 2023, 39( 8): 1819- 1824. DOI: 10.3969/j.issn.1001-5256.2023.08.009.
[21]	MEI LY, HUANG LJ. Research progress of TCM intervention on adverse reactions in interferon treatment for chronic hepatitis B[J]. Chin J Med Guide, 2022, 24( 3): 253- 257. DOI: 10.3969/j.issn.1009-0959.2022.03.013. 梅灵月, 黄利坚. 干扰素治疗慢性乙型肝炎不良反应的中医药干预研究进展[J]. 中国医药导刊, 2022, 24( 3): 253- 257. DOI: 10.3969/j.issn.1009-0959.2022.03.013.
[22]	LIANG HQ, TANG JM, WU CC, et al. Treatment of HBeAg positive chronic hepatitis B by Xiaoyao Powder combined with interferon-α: A clinical observation[J]. Chin J Integr Tradit West Med, 2014, 34( 6): 666- 670. DOI: 10.7661/CJIM.2014.06.0666. 梁惠卿, 唐金模, 吴春城, 等. 逍遥散联合α干扰素治疗HBeAg阳性慢性乙型肝炎的临床观察[J]. 中国中西医结合杂志, 2014, 34( 6): 666- 670. DOI: 10.7661/CJIM.2014.06.0666.
[23]	SUN CH, YANG J, PAN LH, et al. Improvement of icaritin on hematopoietic function in cyclophosphamide-induced myelosuppression mice[J]. Immunopharmacol Immunotoxicol, 2018, 40( 1): 25- 34. DOI: 10.1080/08923973.2017.1392564.
[24]	QIN PY, SONG YL, TAN ZF. Research progress on traditional Chinese medicine in prevention and treatment of post-chemotherapy myelosuppression[J]. Henan Tradit Chin Med, 2024, 44( 8): 1290- 1296. DOI: 10.16367/j.issn.1003-5028.2024.08.0235. 秦沛怡, 宋永蕾, 谭兆峰. 中医药防治化疗后骨髓抑制研究进展[J]. 河南中医, 2024, 44( 8): 1290- 1296. DOI: 10.16367/j.issn.1003-5028.2024.08.0235.
[25]	WENG RR. Study on the treatment of chronic viral hepatitis(live-kidney qi deficiency type) with jaweiyigu anjian and IFN-α[D]. Harbin: Heilongjiang University of Chinese Medicine, 2012. 翁蓉蓉. 加味一贯煎联合干扰素-α治疗慢性病毒性乙型肝炎(肝肾阴虚型)的临床观察[D]. 哈尔滨: 黑龙江中医药大学, 2012.
[26]	CHEN L, JIANG XY, HE JS, et al. Effect of Bushen Jianpi recipe on adverse reactions of patients with chronic hepatitis B treated with pegylated interferon[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29( 3): 262- 264. DOI: 10.3969/j.issn.1005-0264.2019.03.022. 陈亮, 姜小艳, 贺劲松, 等. 补肾健脾方对聚乙二醇干扰素治疗慢性乙型肝炎患者不良反应的影响[J]. 中西医结合肝病杂志, 2019, 29( 3): 262- 264. DOI: 10.3969/j.issn.1005-0264.2019.03.022.
[27]	YU HT, WU JH, KANG JJ, et al. Effect of Kangshi series prescriptions combined with α-2b interferon on the efficacy and side effects of chronic hepatitis B[J]. Hubei J Tradit Chin Med, 2010, 32( 4): 20- 21. DOI: 10.3969/j.issn.1000-0704.2010.04.009. 于洪涛, 吴剑华, 康俊杰, 等. 康氏系列方联合α-2b干扰素对慢乙肝疗效及副作用的影响[J]. 湖北中医杂志, 2010, 32( 4): 20- 21. DOI: 10.3969/j.issn.1000-0704.2010.04.009.
[28]	LIU EL, WANG XJ. Correlation between distribution of TCM syndromes and clinical test indicators based on 451 cases chronic viral hepatitis type B[J]. China J Tradit Chin Med Pharm, 2019, 34( 4): 1793- 1795. 刘二丽, 汪晓军. 451例慢性乙型病毒性肝炎患者中医证型分布及与临床检验指标的相关性[J]. 中华中医药杂志, 2019, 34( 4): 1793- 1795.
[29]	ZHANG X. Systematic review and meta-analysis of the influence of traditional Chinese medicine treatment on HBsAg quantification and HBsAg negative conversion in chronic HBV infection patients[D]. Wuhan: Hubei University of Chinese Medicine, 2021. 张旭. 中药治疗对慢性HBV感染者HBsAg定量、HBsAg阴转影响的系统评价和Meta分析[D]. 武汉: 湖北中医药大学, 2021.
[30]	WU XW. Real-world study on the treatment of chronic viral hepatitis B with traditional Chinese medicine decoction combined with peginterferon α-2b[D]. Fuzhou: Fujian University of Traditional Chinese Medicine, 2023. 吴晓纹. 中药汤剂联合聚乙二醇干扰素α-2b治疗慢性乙型病毒性肝炎的真实世界研究[D]. 福州: 福建中医药大学, 2023.